%0 Journal Article
%T Targeted therapy for metastatic renal cell carcinoma: Current treatment and future directions
%A Noura Majid
%A Nabil Ismaili
%A Mounia Amzerin
%A Hassan Errihani
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2013
%V 2
%N 3
%R 10.4103/2278-0513.119257
%P 195-201
%X Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 3% of all adult cancers. The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being a predominantly cytokine-based treatment to the use of targeted agents, which include Sorafenib, Sunitinib, Bevacizumab, Temsirolimus, Everolimus, Pazopanib, Axitinib, and most recently Tivozanib. Despite these advances mRCC remains a major health problem. Additional studies are needed to optimize the use of these agents in both advanced and early stage disease, either in combination or sequentially. In addition the development of biomarkers should be a priority in order to guide rational tailored development of emerging agents. This literature review was conducted using PubMed, Medline, and Cochrane databases for articles published until January 2013. Abstracts from relevant meeting of the American Society of Clinical Oncology and the European society of medical oncology were also included.
%U https://ccij-online.org/article/targeted-therapy-for-metastatic-renal-cell-carcinoma:-current-treatment-and-future-directions-115